MedTrace Logo

Insulin Degludec vs Insulin Glargine for Glycemic Control in Critical Illness Hyperglycemia

NCT06178874 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2024-08-05

No results posted yet for this study

Summary

The role of ultralong insulin in the control of the blood glucose level in diabetic patients is well known, the current study will discuss the role of ultralong insulin in controlling of hyperglycaemia in critical illness defined as failure or impending failure of an organ

Conditions

  • Glycemic Control
  • Insulin
  • Critical Illness

Interventions

DRUG

Insulin Glargine

hyperglycemic control

DRUG

Insulin Degludec

hyperglycemic control

DRUG

Insulin regular

hyperglycemic control

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2024-05-25
Completion
2024-06-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06178874 on ClinicalTrials.gov